Abexinostat

Phase 3Small molecule

XXynomic Pharmaceuticals, Inc.

Abexinostat is one of 109 small molecule programs targeting Renal Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Cell CarcinomaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Follicular LymphomaActive, not recruiting

Renal Cell CarcinomaPhase 3

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 1

Active, not recruiting

Follicular LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

363 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

31 2

Votrient

Novartis

Phase 3

25 3

Nexavar

Bayer

Phase 3

23 4

Lenvima

Eisai

Phase 3

21 5

Inlyta

PPrism Pharmaceuticals

Phase 3

27 6

Tecentriq

Roche

Phase 3

8 7

Imjudo

AstraZeneca

Phase 3

3 8

Imfinzi

AstraZeneca

Phase 3

2 9

Depo-Provera

Eli Lilly

Phase 3

1 10

TKI258

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Diffuse Large B-Cell Lymphoma

NCT03936153

Q2 2028

Phase 3Recruiting

Renal Cell Carcinoma

NCT03592472

Q4 2029

Phase 2Active, not recruiting

Follicular Lymphoma

NCT03600441

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma2 trials

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting·XXynomic Pharmaceuticals, Inc.·Phase 2·NCT03936153·170 enrolled

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03939182·15 enrolled

Follicular Lymphoma2 trials

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Active, not recruiting·XXynomic Pharmaceuticals, Inc.·Phase 2·NCT03934567·87 enrolled

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

Active, not recruiting·XXynomic Pharmaceuticals, Inc.·Phase 2·NCT03600441·139 enrolled

Tics1 trial

A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

Active, not recruiting·XXynomic Pharmaceuticals, Inc.·Phase 1/2·NCT04024696·12 enrolled

Solid Tumor Malignancies1 trial

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Completed·RRahul Aggarwal·Phase 1·NCT03590054·35 enrolled

Renal Cell Carcinoma1 trial

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Recruiting·XXynomic Pharmaceuticals, Inc.·Phase 3·NCT03592472·413 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Abexinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Abexinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Abexinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xynomic Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: XXynomic Pharmaceuticals, Inc.

Abexinostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Q4 2029

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma2 trials

Follicular Lymphoma2 trials

Tics1 trial

Solid Tumor Malignancies1 trial

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News